About Michael Jaramillo

This author has not yet filled in any details.
So far Michael Jaramillo has created 20 blog entries.

Flamingo Therapeutics Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Danvatirsen in Phase 1 for AML/MDS Cancers

Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy.

Go to Top